Drugmakers Agree To Negotiate Prices In Medicare Despite Attempts To Rid Of Program
The agency will publish the agreed-upon prices by September of next year and those prices will take effect in 2026.
The drug makers chosen for Medicare’s priced negotiation program have agreed to participate in the historic initiative.
The drugs that are set to receive price changes include Eliquis, Jardiance, Xarelto, Januvia, Farxiga, Entresto, Enbrel, Imbruvica and Stelara, as well as Fiasp and certain other insulins made by Novo Nordisk, including NovoLog.
Manufacturers, Bristol Myers Squibb, Merck, Johnson & Johnson’s Janssen division, Novo Nordisk and AstraZeneca, along with others, will now be hosting discussions with the centers for Medicare and Medicaid services to determine maximum fair prices for their products.
The agency will publish the agreed-upon prices by September of next year and those prices will take effect in 2026. Though they have agreed, the drug makers are not giving up their efforts to overturn the program in court.
